Advances in TRK Inhibitor Therapy and NTRK Fusion Testing

Advances in TRK Inhibitor Therapy and NTRK Fusion Testing (July 2020)

Wednesday, July 15, 2020
Webinar -- 12:00 PM ET


  • Welcome and Introduction
  • Rationale for Targeting TRK in Solid Tumors and Key Aspects of Diagnostic Testing (George D. Demetri, MD)
  • Clinical Data and Current Indications for TRK Inhibitors in Multiple Cancer Settings (Pashtoon Kasi, MD)
  • TRK Inhibitor Resistance, Second-Generation Agents, and Safety (Alexander Drilon, MD)
  • Final Thoughts and Audience Question and Answer Session


Program Director
George Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Pashtoon M. Kasi, MD, MS

Director, Colon Cancer Research and Precision
Medical Director for Liquid Biopsy
Weill Cornell Medicine/Englander Institute of Precision Medicine
Assistant Professor (Interim)
Weill Cornell Medicine
New York, New York

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to test for NTRK fusion and integrate TRK inhibitors into the treatment of patients with cancer.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the biology of and rationale for targeting cancers containing NTRK fusions
  • Identify patients with cancer who should be tested for NTRK fusions with established and emerging biomarker assays
  • Describe the research data supporting the use of TRK inhibition in a range of cancers harboring NTRK fusions
  • Formulate strategies for using TRK inhibitors in clinical practice
  • Develop treatment strategies for patients who develop acquired resistance to first-generation TRK inhibitor therapy
  • Refer adult and pediatric patients to ongoing late-phase clinical trials of TRK inhibitors


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.